Core Viewpoint - The company Kaisheng New Materials (301069.SZ) is expanding its market for PEKK products, which can be utilized in the electric vehicle sector [1] Group 1 - The company is actively working on market expansion for its PEKK products [1]

Core Viewpoint - The company is actively expanding its applications of PEKK products in various sectors, including additive manufacturing, spraying, and military aerospace, while also exploring opportunities in electronic information, rehabilitation medical devices, and robotics [1] Group 1 - The company's PEKK products are already being utilized in multiple fields [1] - The company is closely monitoring developments in lightweight special materials for electronic information, rehabilitation medical devices, and robotics [1] - The company is actively seeking to expand its domestic and international markets [1]

Core Viewpoint - The company, Kaisheng New Materials (301069.SZ), is actively expanding its applications of PEKK products across various sectors, including additive manufacturing, spraying, and military aerospace [1] Group 1: Product Applications - The company's PEKK products are already being utilized in multiple fields such as additive manufacturing, spraying, and military aerospace [1] - The company is closely monitoring developments in lightweight specialty materials in sectors like electronic information, rehabilitation medical devices, and robotics [1] Group 2: Market Expansion - The company is actively exploring both domestic and international markets for its products [1]

Core Viewpoint - The equity change is primarily due to the exchange of bonds by the bondholders of Huabang Health, resulting in a decrease in the controlling shareholder's stake from 32.49% to 31.68%, which touches the 1% integer multiple threshold [1][5]. Group 1: Equity Change Details - Huabang Health issued non-public exchangeable bonds with a total scale of 600 million yuan, with an initial conversion price of 14.88 yuan per share, adjusted to 14.83 yuan per share after the 2024 annual equity distribution [1]. - The exchange period for the bonds began on October 23, 2025, and will last until April 21, 2028, allowing bondholders to convert their bonds into company shares [2]. - From October 23 to October 27, 2025, bondholders exchanged a total of 21,186,747 shares, reducing Huabang Health's stake from 39.75% to 34.72% [2]. - On October 28, 2025, an additional 4,369,515 shares were exchanged, further reducing Huabang Health's stake to 33.68% [3]. - Between October 29 and October 30, 2025, bondholders exchanged 4,973,021 shares, bringing Huabang Health's stake down to 32.49% [3]. - On November 3, 2025, the final exchange of 3,425,485 shares was reported, resulting in a decrease of Huabang Health's stake to 31.68% [3]. Group 2: Regulatory Compliance and Impact - The equity change does not trigger a mandatory tender offer and will not lead to changes in the controlling shareholder or actual controller, nor will it significantly impact the company's governance structure or ongoing operations [1][5]. - All shares involved in the equity change retain voting rights, and there are no restrictions on the transfer of these shares [5]. - The company will continue to monitor the exchange situation and fulfill its information disclosure obligations as required by relevant laws and regulations [5].

| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-049 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于控股股东非公开发行可交换公司债券换股进展 暨权益变动比例触及1%整数倍的公告 公司控股股东华邦生命健康股份有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致， 并保证披露的公司相关信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 重要提示： 1.本次权益变动主要系山东凯盛新材料股份有限公司（以下简称"公司"或 "本公司"）控股股东华邦生命健康股份有限公司(以下简称"华邦健康")发行 的华邦健康 2025 年面向专业机构投资者非公开发行可交换公司债券（债券简称 "25 华邦 EB"，债券代码"117227"，以下简称"本次可交换债券"）的债券持 有人换股，导致控股股东持股比例被动从 32.49%减少至 31.68%，权益变动触及 1%的整数倍。 2.本次权益变动不触及要约收购 ...

| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-048 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于控股股东非公开发行可交换公司债券换股进展 暨权益变动比例触及1%整数倍的公告 公司控股股东华邦生命健康股份有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 华邦健康于 2025 年 4 月 22 日面向专业投资者非公开发行可交换公司债券 （以下简称"本期可交换债券"），并于 2025 年 4 月 28 日起在深圳证券交易所挂 牌交易，债券简称"25 华邦 EB"，债券代码"117227"，发行规模 6 亿元，期限 3 年，初始换股价格为 14.88 元/股。2025 年 4 月 30 日，因公司实施 2024 年度权 - 1 - 益分派，"25 华邦 EB" 的换股价格由 14.88 元/股调整为 14.83 元/股。 "25 华邦 EB"于 2025 年 10 月 23 日进入换股期，换股期限为 2025 年 10 月 23 日起至 2028 年 4 ...

Core Viewpoint - The company, Kaisheng New Materials (301069.SZ), has not yet engaged in direct business cooperation with Tesla as of the current date [1] Summary by Relevant Categories - **Company Status** - Kaisheng New Materials has confirmed that it has not established any direct business collaboration with Tesla up to now [1]

Core Viewpoint - Kaisheng New Materials, a leading global producer of thionyl chloride, is positioned for future growth with strong financial performance and technological advancements in its product offerings [2][5]. Group 1: Company Overview - Established on December 20, 2005, Kaisheng New Materials was listed on the Shenzhen Stock Exchange on September 27, 2021, with its headquarters in Zibo, Shandong Province [1]. - The company specializes in fine chemical products and new polymer materials, leveraging its technological and industrial chain advantages [1]. Group 2: Financial Performance - For Q3 2025, Kaisheng New Materials reported revenue of 774 million yuan, ranking 10th in the industry, significantly lower than the top competitor, Satellite Chemical, which had revenue of 34.77 billion yuan [2]. - The company's net profit for the same period was 116 million yuan, ranking 2nd in the industry, only behind Satellite Chemical's 3.76 billion yuan [2]. Group 3: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 29.18%, down from 32.70% year-on-year, and below the industry average of 46.56%, indicating strong solvency [3]. - The gross profit margin for Q3 2025 was 27.78%, an increase from 23.87% year-on-year, and higher than the industry average of 11.02%, reflecting robust profitability [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.54% to 31,400, while the average number of circulating A-shares held per shareholder increased by 4.55% to 12,500 [5]. - Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 2.6049 million shares, a decrease of 647,300 shares from the previous period [5]. Group 5: Future Outlook - Analysts at Huazheng Securities project that Kaisheng New Materials will achieve net profits of 145 million yuan, 190 million yuan, and 250 million yuan for the years 2025 to 2027, with corresponding price-to-earnings ratios of 69, 53, and 40 times [5]. - The company is expected to benefit from the upcoming ramp-up of PEKK production, filling a domestic technological gap, and has already commenced 1,000 tons/year production capacity [5].

| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于控股股东非公开发行可交换公司债券换股进展 暨权益变动比例触及1%整数倍的公告 公司控股股东华邦生命健康股份有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致， 并保证披露的公司相关信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 重要提示： 1.本次权益变动主要系山东凯盛新材料股份有限公司（以下简称"公司"或 "本公司"）控股股东华邦生命健康股份有限公司(以下简称"华邦健康")发行 的华邦健康 2025 年面向专业机构投资者非公开发行可交换公司债券（债券简称 "25 华邦 EB"，债券代码"117227"，以下简称"本次可交换债券"）的债券持 有人换股，导致控股股东持股比例被动从 34.72%减少至 33.68%，权益变动触及 1%的整数倍。 2.本次权益变动不触及要约收购 ...

| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于控股股东非公开发行可交换公司债券换股进展 暨权益变动比例触及5%整数倍的提示性公告 公司控股股东华邦生命健康股份有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致， 并保证披露的公司相关信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 重要提示： 1、本次权益变动主要系山东凯盛新材料股份有限公司（以下简称"公司" 或"本公司"）控股股东华邦生命健康股份有限公司(以下简称"华邦健康")发 行的华邦健康 2025 年面向专业机构投资者非公开发行可交换公司债券（债券简 称"25 华邦 EB"，债券代码"117227"，以下简称"本次可交换债券"）的债券 持有人换股，导致控股股东持股比例被动从 39.75%减少至 34.72%，权益变动比 例已触及 5%的整数倍。 2025 年 1 ...